Kangmei Pharmaceutical Overstated Cash Position by $4.4 Billion

Posted on 05/01/2019

Based in China’s Guangdong province, Kangmei Pharmaceutical Company Limited is a listed company and manufacturer of traditional Chinese medicines. Some of the company’s key products include American ginseng, salvia powder, angelica, and other Chinese herbal medicines.

In a recent filing, the company said that an accounting “error” led to a major overstatement of its 2017 cash position. Kangmei Pharmaceutical overstated its cash position by US$ 4.4 billion.

Kangmei Pharmaceutical faces a possibility of being delisted if the China Securities Regulatory Commission (CSRC) finds the behavior as a major legal violation.

The China Investment Corporation (CIC) owns around 78,380,000 shares of Kangmei Pharmaceutical, or a 1.78% stake as of December 2018. Norges Bank Investment Management, manager of Norway Government Pension Fund Global, owns 6,090,000 shares in the company as of December 2018.

Get News, People, and Transactions, Delivered to Your Inbox